$MDT

Medtronic (MDT) Sees $94.9 Million in Net ETF Selling on Oct. 16

Medtronic (MDT) experienced $94.9 million in net ETF selling on Oct. 16, driven by IHI, JVAL, and KNG. Over the last 5 days, ETFs were net buyers on 2 days and net sellers on 3. MDT reported $37.54 billion in trailing-12-month revenue, with a 2.95% dividend yield and a 0.95% YTD decline.

Original reporting
Published Oct 20, 2026, 11:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medtronic (MDT) Sees $94.9 Million in Net ETF Selling on Oct. 16 — source image
Decision brief

The 30-second read

$MDTBearishLow
01

Why it matters

ETF outflows of this magnitude can create short‑term price pressure, but without accompanying corporate news the effect may be short‑lived.

02

Market read

Provides a data point for traders monitoring institutional flow in healthcare stocks.

03

What to watch

The article does not discuss any corporate news; the sell‑off may be driven by broader market rotation rather than company‑specific issues.

Relevance 4/10Novelty 3/10Timing: after‑hours Friday

Background

The piece reports recent ETF trading activity for Medtronic, highlighting net selling on a specific day.

Company-level read

Ticker impact

$MDTBearishMedium confidence
Context

ETF activity on Oct. 16 resulted in $94.9 M net selling of Medtronic shares, the largest daily outflow reported.

Expected impact

downward pressure as the market prices in the net selling

Evidence & confidence

Large net sell amount ($94.9 M) from multiple ETFs suggests short‑term supply pressure on the stock.

Market effects

Medical devices sector may see modest pullback if other large‑cap medtech stocks face similar ETF outflows.

U.S. equity markets could see slight downward bias in healthcare indices.

Limited to U.S. investors; no immediate global ripple.

Counterpoint

ETF outflows could be temporary and present a buying opportunity if fundamentals remain strong.

Key entities

  • Medtronic

    U.S.-listed medical device manufacturer (ticker MDT).

Related articles

$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.